Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$37.31 -1.6%	$33.74	$29.31 ▼ $61.38	$4.53B	0.59	1.38 million shs	810,426 shs
MTSR Metsera	$39.65 -0.9%	$31.62	$12.30 ▼ $47.40	$4.20B	N/A	748,635 shs	752,750 shs
PAHC Phibro Animal Health	$29.44 -1.2%	$26.20	$16.16 ▼ $31.80	$1.21B	0.75	351,966 shs	278,667 shs
PCVX Vaxcyte	$36.24 -0.6%	$34.28	$27.66 ▼ $121.06	$4.70B	1.19	1.46 million shs	880,184 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	+0.61%	-1.94%	+16.21%	-5.95%	-33.90%
MTSR Metsera	+1.37%	-8.55%	+37.90%	+88.81%	+3,998,999,900.00%
PAHC Phibro Animal Health	+1.92%	-2.46%	+21.79%	+65.32%	+57.45%
PCVX Vaxcyte	+2.07%	-0.30%	+9.65%	+5.65%	-56.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTK Cytokinetics	4.2357 of 5 stars	4.5	1.0	0.0	4.6	3.2	0.8	0.0
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	4.1564 of 5 stars	0.9	4.0	2.5	1.1	4.0	3.3	2.5
PCVX Vaxcyte	1.886 of 5 stars	3.6	1.0	0.0	0.0	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	90.09% Upside
MTSR Metsera	3.00	Buy	$55.00	38.71% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-17.12% Downside
PCVX Vaxcyte	3.10	Buy	$136.50	276.66% Upside

Current Analyst Ratings Breakdown

Latest PAHC, PCVX, MTSR, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00
6/9/2025	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $53.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00
5/14/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
5/13/2025	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $53.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$18.47M	241.25	N/A	N/A	($1.15) per share	-32.44
MTSR Metsera	N/A	N/A	N/A	N/A	($2.46) per share	N/A
PAHC Phibro Animal Health	$1.02B	1.17	$2.13 per share	13.83	$6.34 per share	4.64
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	37.74	14.02	0.49	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)

Latest PAHC, PCVX, MTSR, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CYTK Cytokinetics	-$1.32	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PCVX Vaxcyte	-$1.12	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/12/2025	Q1 2025	MTSR Metsera	N/A	-$1.03	N/A	-$1.03	N/A	N/A
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.63%	N/A	61.54%	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Latest PAHC, PCVX, MTSR, and CYTK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	5.99	5.99
MTSR Metsera	N/A	6.55	6.55
PAHC Phibro Animal Health	2.67	2.91	1.23
PCVX Vaxcyte	N/A	17.70	17.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
MTSR Metsera	N/A
PAHC Phibro Animal Health	99.34%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.70%
MTSR Metsera	N/A
PAHC Phibro Animal Health	50.07%
PCVX Vaxcyte	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable

PAHC, PCVX, MTSR, and CYTK Headlines

Recent News About These Companies

New York State Common Retirement Fund Increases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 22 at 5:58 AM | marketbeat.com

Jennison Associates LLC Has $42.51 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 20, 2025 | marketbeat.com

C WorldWide Group Holding A S Makes New $3.59 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

July 18, 2025 | marketbeat.com

Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)

July 16, 2025 | insidermonkey.com

Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by TimesSquare Capital Management LLC

July 15, 2025 | marketbeat.com

Principal Financial Group Inc. Has $17.73 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 11, 2025 | marketbeat.com

Brown Advisory Inc. Acquires 14,049 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

July 10, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Lowers Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 4, 2025 | marketbeat.com

Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting

July 2, 2025 | msn.com

86,244 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Peregrine Capital Management LLC

July 2, 2025 | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Recommendation of "Buy" by Brokerages

June 30, 2025 | marketbeat.com

Vaxcyte: Sentiment Is Pushing The Shares Down

June 10, 2025 | seekingalpha.com

Here’s Why Vaxcyte (PCVX) Sold Off in Q1

May 27, 2025 | msn.com

Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?

May 9, 2025 | insidermonkey.com

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | globenewswire.com

Vaxcyte appoints new independent director

May 3, 2025 | uk.investing.com

Vaxcyte Appoints Dr. Olivier Brandicourt to Board

May 1, 2025 | tipranks.com

Vaxcyte, Inc. Appoints Dr. Olivier Brandicourt to Board of Directors to Advance Vaccine Development

May 1, 2025 | quiverquant.comQ

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 1, 2025 | globenewswire.com

Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?

April 29, 2025 | insidermonkey.com

Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options

April 23, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC, PCVX, MTSR, and CYTK Company Descriptions

Cytokinetics NASDAQ:CYTK

$37.31 -0.62 (-1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$37.58 +0.27 (+0.71%)

As of 06:11 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Metsera NASDAQ:MTSR

$39.65 -0.34 (-0.85%)

As of 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Phibro Animal Health NASDAQ:PAHC

$29.44 -0.35 (-1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$29.43 -0.01 (-0.03%)

As of 06:17 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Vaxcyte NASDAQ:PCVX

$36.24 -0.22 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$36.18 -0.05 (-0.15%)

As of 07:36 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time